Genotyping and Phenotyping the Hepatitis C Drug Target NS5A

丙型肝炎药物靶点 NS5A 的基因分型和表型分析

• 批准号: 8195980
• 负责人: ROBERT T STRIKER
• 金额: --
• 依托单位: WM S. MIDDLETON MEMORIAL VETERANS HOSP
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8195980
• 关键词: Adverse effects; Affinity; Antiviral Agents; Antiviral Therapy; Biochemical; Breeding; Caring; Cataloging; Catalogs; Cells; Chronic Hepatitis C; Clinical Data; Clinical Trials; Communicable Diseases; Consensus Sequence; Contracts; Cost of Illness; Cyclophilins; Cyclosporine; Data; Databases; Development; Disease; Drug Combinations; Drug Delivery Systems; Drug toxicity; Epidemic; Evolution; FDA approved; Family; Genetic; Genetic Databases; Genetic Recombination; Genetic Variation; Genotype; HIV; Health; Healthcare Systems; Hepatitis C; Hepatitis C virus; Immune; Immunoprecipitation; Immunosuppression; Immunosuppressive Agents; In Vitro; Industry; Interferons; Investments; Lead; Light; Link; Liver; Liver diseases; Malignant neoplasm of liver; Mono-S; Morbidity - disease rate; Non-Hodgkin' s Lymphoma; Nonstructural Protein; Organ Transplantation; Outcome; Patient Care; Patients; Peptidylprolyl Isomerase; Pharmaceutical Preparations; Pharmacogenomics; Phase; Phenotype; Population; Predisposition; Proteins; Public Health; Recombinants; Relative (related person); Replicon; Research; Research Design; Research Methodology; Resistance; Resistance development; Resources; Ribavirin; Role; Sampling; Serum; Site; Solid; Staging; System; Testing; Therapeutic; Time; Transfusion; Transplant Recipients; Transplantation; United States; United States Department of Veterans Affairs; Variant; Veterans; Vietnam; Viral; Viral Nonstructural Proteins; Viral Proteins; Viral Regulatory Proteins; Viremia; Virus; anti-hepatitis C; base; burden of illness; combat; cost; cyclophilin B; effective therapy; fitness; functional genomics; high risk; improved; in vivo; inhibitor/antagonist; insight; liver transplantation; mortality; mutant; pathogen; pre-clinical; pressure; prevent; protein folding; public health relevance; response; risk benefit ratio; small molecule; treatment response; treatment strategy; viral resistance; virus genetics